Logo

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Share this

Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma

Shots:

  • The US FDA has accepted the BLA for toripalimab + CT (gemcitabine & cisplatin) & toripalimab as monothx. to treat advanced recurrent or metastatic NPC after platinum-containing CT. The US FDA has granted PR designation of toripalimab BLA with an anticipated PDUFA date on Apr'22
  • The BLA is based on the P-II POLARIS-02 & P-III JUPITER-02 study. In 2021, Coherus got the licensed rights to develop and commercialize toripalimab in the US and Canada
  • In Aug'21, toripalimab + CT has received the BTD for recurrent, LA, or primary metastatic non-keratinizing NPC. Additionally, both companies plan to file additional toripalimab's BLA with the US FDA over the next 3yrs.  for multiple cancer article

 Ref: Globe Newswire | Image: Coherus

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions